United States - English - NLM (National Library of Medicine)

avera mckennan hospital - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution ( 5.1 ) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the

United States - English - NLM (National Library of Medicine)

avkare - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution ( 5.1 ) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to t

United States - English - NLM (National Library of Medicine)

atlantic biologicals corp. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution ( 5.1 ) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopment disorders, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy or bipolar disorder who

Canada - English - Health Canada

apotex inc - valproic acid - capsule - 250mg - valproic acid 250mg - miscellaneous anticonvulsants

Canada - English - Health Canada

apotex inc - valproic acid (sodium valproate) - solution - 250mg - valproic acid (sodium valproate) 250mg - miscellaneous anticonvulsants

United States - English - NLM (National Library of Medicine)

abbvie inc. - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - depakene (valproic acid) is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. depakene (valproic acid) is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neurodevelopmental disorders , neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be used to treat women with epilepsy

Israel - English - Ministry of Health

sanofi israel ltd - valproic acid; valproic acid as sodium - tablets prolonged release - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid - epilepsy:treatment of generalized or partial epilepsy secondary epilepsy and mixed forms of epilepsy. bipolar disorders: treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. the continuation of treatment after manic episode could be considered in patients who have responded to valproic acid for acute mania.

Canada - English - Health Canada

pharmascience inc - valproic acid - capsule (enteric-coated) - 500mg - valproic acid 500mg - miscellaneous anticonvulsants

Canada - English - Health Canada

pharmascience inc - valproic acid - capsule - 250mg - valproic acid 250mg - miscellaneous anticonvulsants